Three months after joining forces to develop an adjuvanted vaccine for Covid-19, Sanofi and GlaxoSmithKline reached an agreement with the U.K. government to provide up to 60 million doses of the preventative medication.

GlaxoSmithKline is providing pandemic adjuvant technology to another company to bolster the chances of developing a vaccine against COVID-19.

GlaxoSmithKline, the world’s largest vaccine maker, said the global push to develop an immunization against the coronavirus would not lead to widely available products before the second half of 2021.

California-based Dynavax Technologies entered the race alongside Sinovac Biotech to develop a vaccine candidate against COVID-19.

According to the World Health Organization (WHO), there are more than 70 potential vaccines under development, with three already in clinical trials.

As the world continues to wait for a vaccine against COVID-19, GlaxoSmithKline and Sanofi joined forces to develop an adjuvanted vaccine for COVID-19.